SOVALDI® (PELLETS)

Drug Information Related Patent

Hold Company

GILEAD SCIENCES INC

Learn More

Dosage and Administration

PELLETS;ORAL

Specification

150MG/PACKET; 200MG/PACKET

Indication

SOVALDI® is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults. It can also be used in the treatment of 3 years or above of compensatory cirrhosis of the liver cirrhosis or chronic infection of HCV genotype 2 or 3 children.

Use

Instructions for Use

API

SOFOSBUVIR

API Structure

We Supply

SOFOSBUVIR

Note:

Facility GMP
DMF/WHO-APIMF/CDE/USMF

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
7964580	2029/3/26
7964580*PED	2029/9/26
8334270	2028/3/21
8334270*PED	2028/9/21
8580765	2028/3/21
8580765*PED	2028/9/21
8618076	2030/12/11
8618076*PED	2031/6/11
8633309	2029/3/26
8633309*PED	2029/9/26
8889159	2029/3/26
8889159*PED	2029/9/26
9085573	2028/3/21
9085573*PED	2028/9/21
9284342	2030/9/13
9284342*PED	2031/3/13

API Patent

Patent No	Expiration Date
7964580	2029/3/26
7964580*PED	2029/9/26
8334270	2028/3/21
8334270*PED	2028/9/21
8580765	2028/3/21
8580765*PED	2028/9/21
8633309	2029/3/26
8633309*PED	2029/9/26
9085573	2028/3/21
9085573*PED	2028/9/21

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.